Next Article in Journal
Development of an Organ-Directed Exosome-Based siRNA-Carrier Derived from Autologous Serum for Lung Metastases and Testing in the B16/BL6 Spontaneous Lung Metastasis Model
Previous Article in Journal
Current and Future Treatments for Diabetic Retinopathy
Previous Article in Special Issue
Mass Cytometry Exploration of Immunomodulatory Responses of Human Immune Cells Exposed to Silver Nanoparticles
 
 
Article

A New Generation of Ultrasmall Nanoparticles Inducing Sensitization to Irradiation and Copper Depletion to Overcome Radioresistant and Invasive Cancers

1
Institut Lumière Matière, Université Claude Bernard Lyon 1CNRS UMR 5306, 69622 Villeurbanne, France
2
NH TherAguix SA, 38240 Meylan, France
3
Cellular and Molecular Radiobiology Laboratory, Lyon-Sud Medical School, UMR CNRS 5822/IP2I, Univ. Lyon, Lyon 1 University, 69921 Oullins, France
4
Institut Universitaire de France (IUF), 75000 Paris, France
5
LiPhy, Université Grenoble Alpes, CNRS, UMR UMR5588, 38401 Grenoble, France
6
Ingénierie des Matériaux Polymères, Université de Lyon, Université Claude Bernard Lyon 1, Université Jean Monet, Institut National des Sciences Appliquées de Lyon, CNRS, UMR 5223, 15, bd A. Latarjet, 69622 Villeurbanne, France
7
Department of Biochemistry and Molecular Biology, Lyon-Sud Hospital, Hospices Civils of Lyon, 69310 Pierre-Bénite, France
*
Author to whom correspondence should be addressed.
These authors contribute equally to the work.
Academic Editor: Leonard I. Wiebe
Pharmaceutics 2022, 14(4), 814; https://doi.org/10.3390/pharmaceutics14040814
Received: 24 February 2022 / Revised: 23 March 2022 / Accepted: 29 March 2022 / Published: 7 April 2022
An emerging target to overcome cancer resistance to treatments is copper, which is upregulated in a wide variety of tumors and may be associated with cancer progression and metastases. The aim of this study was to develop a multimodal ultrasmall nanoparticle, CuPRiX, based on the clinical AGuIX nanoparticle made of the polysiloxane matrix on which gadolinium chelates are grafted. Such hybrid nanoparticles allow: (i) a localized depletion of copper in tumors to prevent tumor cell dissemination and metastasis formation and (ii) an increased sensitivity of the tumor to radiotherapy (RT) due to the presence of high Z gadolinium (Gd) atoms. CuPRiX nanoparticles are obtained by controlled acidification of AGuIX nanoparticles. They were evaluated in vitro on two cancer cell lines (lung and head and neck) using the scratch-wound assay and clonogenic cell survival assay. They were able to reduce cell migration and invasion and displayed radiosensitizing properties. View Full-Text
Keywords: copper depletion; ultrasmall nanoparticle; radiosensitization copper depletion; ultrasmall nanoparticle; radiosensitization
Show Figures

Figure 1

MDPI and ACS Style

Rocchi, P.; Brichart-Vernos, D.; Lux, F.; Morfin, I.; David, L.; Rodriguez-Lafrasse, C.; Tillement, O. A New Generation of Ultrasmall Nanoparticles Inducing Sensitization to Irradiation and Copper Depletion to Overcome Radioresistant and Invasive Cancers. Pharmaceutics 2022, 14, 814. https://doi.org/10.3390/pharmaceutics14040814

AMA Style

Rocchi P, Brichart-Vernos D, Lux F, Morfin I, David L, Rodriguez-Lafrasse C, Tillement O. A New Generation of Ultrasmall Nanoparticles Inducing Sensitization to Irradiation and Copper Depletion to Overcome Radioresistant and Invasive Cancers. Pharmaceutics. 2022; 14(4):814. https://doi.org/10.3390/pharmaceutics14040814

Chicago/Turabian Style

Rocchi, Paul, Delphine Brichart-Vernos, François Lux, Isabelle Morfin, Laurent David, Claire Rodriguez-Lafrasse, and Olivier Tillement. 2022. "A New Generation of Ultrasmall Nanoparticles Inducing Sensitization to Irradiation and Copper Depletion to Overcome Radioresistant and Invasive Cancers" Pharmaceutics 14, no. 4: 814. https://doi.org/10.3390/pharmaceutics14040814

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop